Home » Stocks » Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. (ZNTL)

Stock Price: $47.97 USD 0.17 (0.36%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.72B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 35.88M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $47.97
Previous Close $47.80
Change ($) 0.17
Change (%) 0.36%
Day's Open 48.51
Day's Range 46.00 - 48.98
Day's Volume 78,056
52-Week Range 22.00 - 59.32

More Stats

Market Cap 1.72B
Enterprise Value 1.66B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 35.88M
Float 14.73M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.42M
Short Ratio 7.91
Short % of Float 12.44%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 16.12
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 64.06M
Net Cash / Share 1.79
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(-6.71% downside)
Current: 47.97
Target: 44.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-0.01
Operating Income-46.85-23.78
Net Income-45.66-21.07
Shares Outstanding5.605.59
Earnings Per Share-8.16-3.77
Operating Cash Flow-39.14-24.25
Capital Expenditures-0.35-0.23
Free Cash Flow-39.50-24.48
Cash & Equivalents67.4925.15
Net Cash / Debt67.4925.15
Book Value-80.1124.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zentalis Pharmaceuticals, Inc.
Country United States
Employees 64
CEO Anthony Y. Sun

Stock Information

Ticker Symbol ZNTL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ZNTL


Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.